A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by Eastern Cooperative Oncology Group performance status (ECOG). Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), RECIST tumor assessments and safety laboratory values.
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Study Start Date :
Actual Primary Completion Date :
Estimated Study Completion Date :
Resource links provided by the National Library of Medicine
Evaluate antitumor activity of niraparib [ Time Frame: 6 months ]
Secondary Outcome Measures :
Evaluate durability of anti-cancer activity (i.e. time from first response, CR or PR until disease progression). [ Time Frame: 6 months ]
The evaluation is measured by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), RECIST tumor assessments and safety laboratory values.
Evaluate antitumor activity of niraparib in HRD+ and gBRCAmut [ Time Frame: 6 months ]
To evaluate antitumor activity of niraparib in homologous recombination deficiency (HRD) positive patients and in gBRCAmut positive patients
Disease Control Rate (DCR) [ Time Frame: 6 months ]
Progression Free Survival [ Time Frame: 6 months ]
Time from enrollment to the earlier date of assessment of progression by any cause in the absence of progression per RECIST (v.1.1) or clinical criteria, or death.
Overall Survival [ Time Frame: 6 months ]
Time from enrollment to the date of death by any cause.
Evaluate the safety and tolerability of niraparib in ovarian cancer patients (Review of adverse events, concomitant medications, physical exams, electrocardiograms (ECGs), and safety lab values.) [ Time Frame: 6 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must agree to undergo tumor HRD testing and blood gBRCAmut status testing.
Patients of childbearing potential must have negative pregnancy serum test within 72 hours of being dosed
Patients must have histologically diagnosed high-grade (Grade 2 or 3) serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease and must have been previously treated with chemotherapy and experienced a response lasting at least 6 months to first-line platinum based therapy.
Patients Must have completed 3 or 4 previous chemotherapy regimens.
Patients must have completed their last chemotherapy regimen > 4 weeks prior to treatment initiation.
Patients must have measurable disease according to RECIST (v.1.1).
Patients must have formalin-fixed, paraffin-embedded tumor samples available from the primary or recurrent cancer or agree to undergo fresh biopsy prior to study treatment initiation.
Patients must agree to blood samples during screening and at the end of treatment for cytogenetic analysis.
Patients must not have any known, persistent (> 4 weeks), ≥Grade 3 hematologic toxicity during the last cancer therapy. Patients must not have any known, persistent (>4 weeks), ≥ Grade 3 fatigue during the last cancer therapy.
Patients must not have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.
Patients must not have symptomatic uncontrolled brain or leptomeningeal metastases.
Patients must not be considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection.
Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment.
Patients must not have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).